NTHI
NeOnc Technologies Holdings, Inc.9.44
-0.44-4.45%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
183.84MP/E (TTM)
-Basic EPS (TTM)
-2.51Dividend Yield
0%Recent Filings
8-K
8-K
NeOnc appoints new CEO Heshmatpour
NeOnc Technologies Holdings, Inc. announced on October 31, 2025, that Dr. Thomas Chen resigned as CEO to focus on his roles as Chief Medical Officer and Chief Scientific Officer, while the Board appointed Amir Heshmatpour as CEO, effective immediately, alongside his positions as President and Executive Chairman. Heshmatpour receives $1 annual salary pending a formal agreement and 1,200,000 restricted shares vesting half on January 2, 2026, and the rest monthly. This shift bolsters corporate strategy amid Phase 2 trials, yet ties to prior loans and advisory fees raise governance questions.
8-K
Sheikh Nahyan leads NuroMENA
NeOnc Technologies announced on October 28, 2025, that His Highness Sheikh Nahyan bin Zayed Al Nahyan will assume the role of Executive Chairman of its Middle East subsidiary, NuroMENA Holdings Ltd., with Amir Heshmatpour transitioning to Vice Chairman. This high-profile appointment signals strong backing from UAE sovereign resources, poised to accelerate the company's Phase 2 CNS cancer therapies amid global humanitarian goals. Backing arrives. Yet risks like unmaterialized partnerships loom in forward-looking disclosures.
8-K
NeOnc inks UAE CRO deal
NeOnc Technologies entered a Master Services Agreement on October 4, 2025, with UAE-based Insights Pharmaceutical Research LLC (IROS), an affiliate of M42 and Mubadala, to provide clinical research services for trials in the UAE, transferable to subsidiary NuroCure post-incorporation. The initial work order funds a multi-site Phase 2b/3 study of intranasal NEO100 for glioblastoma and astrocytomas, budgeted at $2.4 million in fees plus $0.1 million pass-through costs, payable in four milestones. This bolsters NeOnc's Middle East expansion, securing elite infrastructure for faster oncology trials. Yet regulatory hurdles loom.
8-K
FDA clears NEO212 Phase II trial
NeOnc Technologies Holdings scored FDA clearance on September 10, 2025, to launch Phase IIa/IIb of its NEO212-01 trial after safely dosing up to 810 mg daily in Phase I. This oral conjugate of Temozolomide and proprietary NEO100 aims to boost brain penetration and combat resistance in glioblastoma and CNS cancers. Enrollment kicks off before year-end across top U.S. centers. Yet risks like trial delays loom large.
BIVI
BioVie Inc.
1.43+0.00
BPTH
Bio-Path Holdings, Inc.
0.08+0.00
BZYR
Burzynski Research Institute, I
0.03-0.00
INTS
Intensity Therapeutics, Inc.
0.44+0.02
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
MAIA
MAIA Biotechnology, Inc.
1.23-0.12
NBTX
Nanobiotix S.A.
22.32+0.18
NVCT
Nuvectis Pharma, Inc.
7.69+0.04
NWBO
Northwest Biotherapeutics, Inc.
0.25+0.01
RNXT
RenovoRx, Inc.
0.84-0.10